HB Wealth Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
DTC
HB Wealth Management's AXSM Position: Q2 2026 in Review
HB Wealth Management increased its Axsome Therapeutics (AXSM) stake by 0.4% in Q2 2026, buying an estimated $44K and bringing the position to 50,440 shares worth $12.3M. The position accounts for 0.07% of the portfolio, ranked #149.
HB Wealth Management first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- HB Wealth Management held 50,440 shares of Axsome Therapeutics worth $12.3M as of Q2 2026.
- HB Wealth Management bought 203 Axsome Therapeutics shares in Q2 2026, an estimated $44K.
- Axsome Therapeutics made up 0.07% of HB Wealth Management's portfolio in Q2 2026, its #149 holding.
- HB Wealth Management first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.